世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

非侵襲的ワクチン接種 - 世界市場シェアとランキング、全体売上高と需要予測 2024-2030


Noninvasive Vaccination - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

非侵襲的ワクチン送達システムには、粘膜免疫反応と全身免疫反応の両方を誘発するように特別に設計された、効果的なアジュバントを組み込む必要がある。 非侵襲的ワクチン接種の世界市場は、2023年には2億6,000... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2024年8月2日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

非侵襲的ワクチン送達システムには、粘膜免疫反応と全身免疫反応の両方を誘発するように特別に設計された、効果的なアジュバントを組み込む必要がある。
非侵襲的ワクチン接種の世界市場は、2023年には2億6,000万米ドルと推定され、2024-2030年の予測期間中のCAGRは5.6%で、2030年には3億9,091万米ドルに再調整されると予測されている。

経口ワクチン市場は、従来の注射ワクチンに比べ、投与が容易で、患者のコンプライアンスが向上し、費用対効果が高いという利点が主な要因です。経口ワクチンは非侵襲的で痛みを伴わない予防接種方法であり、特に小児や高齢者にとっては有益である。さらに、全身免疫と粘膜免疫の両方を誘発する可能性があるため、呼吸器や消化管などの粘膜表面から体内に侵入する病原体に対する防御が強化され、その採用がさらに加速している。しかしながら、経口ワクチンの複雑な製剤化や送達など、安定性や有効性に影響を及ぼす可能性のある課題にも直面している。酸性環境や消化管内での酵素分解に耐えるワクチンの開発には、科学的・製造的に大きな課題がある。さらに、規制当局の承認を得たり、経口ワクチンを一般に受け入れられるようにするには、広範な臨床データや、安全性や有効性に関する誤解を払拭するための啓蒙活動が必要になることもあります。これらの課題を克服するため、業界は経口ワクチンの製剤化および送達技術を改善するための研究と技術革新に注力しています。ワクチン開発企業、研究機関、規制当局の協力は、経口ワクチン市場の成長を促進し、特に医療インフラが限られている地域において、効果的で利用しやすい予防接種オプションへのアクセスを拡大する上で極めて重要である。

レポートの範囲
本レポートでは、非侵襲的ワクチン接種の世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総販売量、販売収益、価格、主要企業の市場シェア、ランキングに焦点を当て、包括的なプレゼンテーションを提供することを目的としています。
非侵襲的ワクチン接種の市場規模、推計、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データおよび予測データとともに、販売数量(K単位)および販売収益(百万ドル)で提供されます。定量分析および定性分析により、読者が事業/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、非侵襲的ワクチン接種に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

市場区分
企業別
メルク
GSK
サノフィ
蘭州研究所
血清研究所
バルネバ
上海ユナイテッドセル
ビブコル
パックスバックス
バビオテック
天壇生物
ユーバイオロジクス
パナセアバイオテック
バイオメッド
ハーフキン・バイオファーマシューティカルズ
アストラゼネカ
シプラ
BCHT
タイプ別セグメント
経口ワクチン
経鼻スプレーワクチン
用途別セグメント
公共
民間
地域別
北米
米国
カナダ
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦

各章の概要
第1章: レポートの対象範囲、世界の総市場規模(バルブ、数量、価格)を紹介。この章ではまた、市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章:非侵襲性ワクチン接種メーカーの競争環境、価格、売上高、市場シェア、最新の開発計画、合併・買収情報などを詳細に分析。
第3章:タイプ別に様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる市場セグメントでブルーオーシャン市場を見つけるのを助ける。
第4章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる川下市場のブルーオーシャン市場を見つけるのに役立ちます。
第5章:地域レベルでの非侵襲的ワクチン接種の売上高、収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。
第6章 国別非侵襲的ワクチン接種の売上高、収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。
第7章:主要企業のプロファイルを提供し、製品の売上高、収益、価格、粗利益率、製品紹介、最近の開発など、市場の主要企業の基本的な状況を詳細に紹介します。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 Noninvasive Vaccination Product Introduction
1.2 Global Noninvasive Vaccination Market Size Forecast
1.2.1 Global Noninvasive Vaccination Sales Value (2019-2030)
1.2.2 Global Noninvasive Vaccination Sales Volume (2019-2030)
1.2.3 Global Noninvasive Vaccination Sales Price (2019-2030)
1.3 Noninvasive Vaccination Market Trends & Drivers
1.3.1 Noninvasive Vaccination Industry Trends
1.3.2 Noninvasive Vaccination Market Drivers & Opportunity
1.3.3 Noninvasive Vaccination Market Challenges
1.3.4 Noninvasive Vaccination Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Noninvasive Vaccination Players Revenue Ranking (2023)
2.2 Global Noninvasive Vaccination Revenue by Company (2019-2024)
2.3 Global Noninvasive Vaccination Players Sales Volume Ranking (2023)
2.4 Global Noninvasive Vaccination Sales Volume by Company Players (2019-2024)
2.5 Global Noninvasive Vaccination Average Price by Company (2019-2024)
2.6 Key Manufacturers Noninvasive Vaccination Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Noninvasive Vaccination Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Noninvasive Vaccination
2.9 Noninvasive Vaccination Market Competitive Analysis
2.9.1 Noninvasive Vaccination Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Noninvasive Vaccination Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Vaccination as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oral Vaccine
3.1.2 Nasal Spray Vaccine
3.2 Global Noninvasive Vaccination Sales Value by Type
3.2.1 Global Noninvasive Vaccination Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Noninvasive Vaccination Sales Value, by Type (2019-2030)
3.2.3 Global Noninvasive Vaccination Sales Value, by Type (%) (2019-2030)
3.3 Global Noninvasive Vaccination Sales Volume by Type
3.3.1 Global Noninvasive Vaccination Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Noninvasive Vaccination Sales Volume, by Type (2019-2030)
3.3.3 Global Noninvasive Vaccination Sales Volume, by Type (%) (2019-2030)
3.4 Global Noninvasive Vaccination Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Public
4.1.2 Private
4.2 Global Noninvasive Vaccination Sales Value by Application
4.2.1 Global Noninvasive Vaccination Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Noninvasive Vaccination Sales Value, by Application (2019-2030)
4.2.3 Global Noninvasive Vaccination Sales Value, by Application (%) (2019-2030)
4.3 Global Noninvasive Vaccination Sales Volume by Application
4.3.1 Global Noninvasive Vaccination Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Noninvasive Vaccination Sales Volume, by Application (2019-2030)
4.3.3 Global Noninvasive Vaccination Sales Volume, by Application (%) (2019-2030)
4.4 Global Noninvasive Vaccination Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Noninvasive Vaccination Sales Value by Region
5.1.1 Global Noninvasive Vaccination Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Noninvasive Vaccination Sales Value by Region (2019-2024)
5.1.3 Global Noninvasive Vaccination Sales Value by Region (2025-2030)
5.1.4 Global Noninvasive Vaccination Sales Value by Region (%), (2019-2030)
5.2 Global Noninvasive Vaccination Sales Volume by Region
5.2.1 Global Noninvasive Vaccination Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Noninvasive Vaccination Sales Volume by Region (2019-2024)
5.2.3 Global Noninvasive Vaccination Sales Volume by Region (2025-2030)
5.2.4 Global Noninvasive Vaccination Sales Volume by Region (%), (2019-2030)
5.3 Global Noninvasive Vaccination Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Noninvasive Vaccination Sales Value, 2019-2030
5.4.2 North America Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Noninvasive Vaccination Sales Value, 2019-2030
5.5.2 Europe Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Noninvasive Vaccination Sales Value, 2019-2030
5.6.2 Asia Pacific Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Noninvasive Vaccination Sales Value, 2019-2030
5.7.2 South America Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Noninvasive Vaccination Sales Value, 2019-2030
5.8.2 Middle East & Africa Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Noninvasive Vaccination Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Noninvasive Vaccination Sales Value
6.2.1 Key Countries/Regions Noninvasive Vaccination Sales Value, 2019-2030
6.2.2 Key Countries/Regions Noninvasive Vaccination Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Noninvasive Vaccination Sales Value, 2019-2030
6.3.2 United States Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Noninvasive Vaccination Sales Value, 2019-2030
6.4.2 Europe Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Noninvasive Vaccination Sales Value, 2019-2030
6.5.2 China Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.5.3 China Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Noninvasive Vaccination Sales Value, 2019-2030
6.6.2 Japan Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Noninvasive Vaccination Sales Value, 2019-2030
6.7.2 South Korea Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Noninvasive Vaccination Sales Value, 2019-2030
6.8.2 Southeast Asia Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Noninvasive Vaccination Sales Value, 2019-2030
6.9.2 India Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.9.3 India Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck Noninvasive Vaccination Product Offerings
7.1.5 Merck Recent Development
7.2 GSK
7.2.1 GSK Company Information
7.2.2 GSK Introduction and Business Overview
7.2.3 GSK Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.2.4 GSK Noninvasive Vaccination Product Offerings
7.2.5 GSK Recent Development
7.3 Sanofi
7.3.1 Sanofi Company Information
7.3.2 Sanofi Introduction and Business Overview
7.3.3 Sanofi Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Sanofi Noninvasive Vaccination Product Offerings
7.3.5 Sanofi Recent Development
7.4 Lanzhou Institute
7.4.1 Lanzhou Institute Company Information
7.4.2 Lanzhou Institute Introduction and Business Overview
7.4.3 Lanzhou Institute Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Lanzhou Institute Noninvasive Vaccination Product Offerings
7.4.5 Lanzhou Institute Recent Development
7.5 Serum Institute
7.5.1 Serum Institute Company Information
7.5.2 Serum Institute Introduction and Business Overview
7.5.3 Serum Institute Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Serum Institute Noninvasive Vaccination Product Offerings
7.5.5 Serum Institute Recent Development
7.6 Valneva
7.6.1 Valneva Company Information
7.6.2 Valneva Introduction and Business Overview
7.6.3 Valneva Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Valneva Noninvasive Vaccination Product Offerings
7.6.5 Valneva Recent Development
7.7 Shanghai United Cell
7.7.1 Shanghai United Cell Company Information
7.7.2 Shanghai United Cell Introduction and Business Overview
7.7.3 Shanghai United Cell Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Shanghai United Cell Noninvasive Vaccination Product Offerings
7.7.5 Shanghai United Cell Recent Development
7.8 Bibcol
7.8.1 Bibcol Company Information
7.8.2 Bibcol Introduction and Business Overview
7.8.3 Bibcol Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Bibcol Noninvasive Vaccination Product Offerings
7.8.5 Bibcol Recent Development
7.9 PaxVax
7.9.1 PaxVax Company Information
7.9.2 PaxVax Introduction and Business Overview
7.9.3 PaxVax Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.9.4 PaxVax Noninvasive Vaccination Product Offerings
7.9.5 PaxVax Recent Development
7.10 Vabiotech
7.10.1 Vabiotech Company Information
7.10.2 Vabiotech Introduction and Business Overview
7.10.3 Vabiotech Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Vabiotech Noninvasive Vaccination Product Offerings
7.10.5 Vabiotech Recent Development
7.11 Tiantan Biological
7.11.1 Tiantan Biological Company Information
7.11.2 Tiantan Biological Introduction and Business Overview
7.11.3 Tiantan Biological Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Tiantan Biological Noninvasive Vaccination Product Offerings
7.11.5 Tiantan Biological Recent Development
7.12 EuBiologics
7.12.1 EuBiologics Company Information
7.12.2 EuBiologics Introduction and Business Overview
7.12.3 EuBiologics Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.12.4 EuBiologics Noninvasive Vaccination Product Offerings
7.12.5 EuBiologics Recent Development
7.13 Panacea Biotec Ltd
7.13.1 Panacea Biotec Ltd Company Information
7.13.2 Panacea Biotec Ltd Introduction and Business Overview
7.13.3 Panacea Biotec Ltd Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Panacea Biotec Ltd Noninvasive Vaccination Product Offerings
7.13.5 Panacea Biotec Ltd Recent Development
7.14 Bio-Med
7.14.1 Bio-Med Company Information
7.14.2 Bio-Med Introduction and Business Overview
7.14.3 Bio-Med Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Bio-Med Noninvasive Vaccination Product Offerings
7.14.5 Bio-Med Recent Development
7.15 Halfkin Bio-Pharmaceuticals
7.15.1 Halfkin Bio-Pharmaceuticals Company Information
7.15.2 Halfkin Bio-Pharmaceuticals Introduction and Business Overview
7.15.3 Halfkin Bio-Pharmaceuticals Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Halfkin Bio-Pharmaceuticals Noninvasive Vaccination Product Offerings
7.15.5 Halfkin Bio-Pharmaceuticals Recent Development
7.16 AstraZeneca
7.16.1 AstraZeneca Company Information
7.16.2 AstraZeneca Introduction and Business Overview
7.16.3 AstraZeneca Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.16.4 AstraZeneca Noninvasive Vaccination Product Offerings
7.16.5 AstraZeneca Recent Development
7.17 Cipla
7.17.1 Cipla Company Information
7.17.2 Cipla Introduction and Business Overview
7.17.3 Cipla Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Cipla Noninvasive Vaccination Product Offerings
7.17.5 Cipla Recent Development
7.18 BCHT
7.18.1 BCHT Company Information
7.18.2 BCHT Introduction and Business Overview
7.18.3 BCHT Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.18.4 BCHT Noninvasive Vaccination Product Offerings
7.18.5 BCHT Recent Development
8 Industry Chain Analysis
8.1 Noninvasive Vaccination Industrial Chain
8.2 Noninvasive Vaccination Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Noninvasive Vaccination Sales Model
8.5.2 Sales Channel
8.5.3 Noninvasive Vaccination Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

Noninvasive vaccine delivery systems need to incorporate an effective adjuvant, specially designed for triggering both mucosal and systemic immune responses.
The global market for Noninvasive Vaccination was estimated to be worth US$ 2670 million in 2023 and is forecast to a readjusted size of US$ 3909.1 million by 2030 with a CAGR of 5.6% during the forecast period 2024-2030

The oral vaccination market is primarily driven by the advantages it offers in terms of ease of administration, increased patient compliance, and cost-effectiveness compared to traditional injectable vaccines. Oral vaccines provide a non-invasive and painless immunization method, particularly beneficial for pediatric and elderly populations. Additionally, their potential to elicit both systemic and mucosal immunity enhances protection against pathogens that enter the body through mucosal surfaces, such as the respiratory and gastrointestinal tracts, further fueling their adoption. However, the market also faces challenges, including the complex formulation and delivery of oral vaccines, which may affect their stability and efficacy. Developing vaccines that can withstand acidic environments and enzymatic degradation in the gastrointestinal tract poses significant scientific and manufacturing challenges. Moreover, gaining regulatory approvals and ensuring public acceptance of oral vaccines may require extensive clinical data and educational efforts to dispel misconceptions about their safety and efficacy. To overcome these challenges, the industry is focused on research and innovation to improve oral vaccine formulation and delivery technologies. Collaborations between vaccine developers, research institutions, and regulatory authorities are crucial in driving the growth of the oral vaccination market and expanding access to effective and accessible immunization options, particularly in regions with limited healthcare infrastructure.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Noninvasive Vaccination, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Noninvasive Vaccination by region & country, by Type, and by Application.
The Noninvasive Vaccination market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Vaccination.

Market Segmentation
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
AstraZeneca
Cipla
BCHT
Segment by Type:
Oral Vaccine
Nasal Spray Vaccine
Segment by Application
Public
Private
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Noninvasive Vaccination manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Noninvasive Vaccination in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Noninvasive Vaccination in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Noninvasive Vaccination Product Introduction
1.2 Global Noninvasive Vaccination Market Size Forecast
1.2.1 Global Noninvasive Vaccination Sales Value (2019-2030)
1.2.2 Global Noninvasive Vaccination Sales Volume (2019-2030)
1.2.3 Global Noninvasive Vaccination Sales Price (2019-2030)
1.3 Noninvasive Vaccination Market Trends & Drivers
1.3.1 Noninvasive Vaccination Industry Trends
1.3.2 Noninvasive Vaccination Market Drivers & Opportunity
1.3.3 Noninvasive Vaccination Market Challenges
1.3.4 Noninvasive Vaccination Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Noninvasive Vaccination Players Revenue Ranking (2023)
2.2 Global Noninvasive Vaccination Revenue by Company (2019-2024)
2.3 Global Noninvasive Vaccination Players Sales Volume Ranking (2023)
2.4 Global Noninvasive Vaccination Sales Volume by Company Players (2019-2024)
2.5 Global Noninvasive Vaccination Average Price by Company (2019-2024)
2.6 Key Manufacturers Noninvasive Vaccination Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Noninvasive Vaccination Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Noninvasive Vaccination
2.9 Noninvasive Vaccination Market Competitive Analysis
2.9.1 Noninvasive Vaccination Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Noninvasive Vaccination Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Vaccination as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Oral Vaccine
3.1.2 Nasal Spray Vaccine
3.2 Global Noninvasive Vaccination Sales Value by Type
3.2.1 Global Noninvasive Vaccination Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Noninvasive Vaccination Sales Value, by Type (2019-2030)
3.2.3 Global Noninvasive Vaccination Sales Value, by Type (%) (2019-2030)
3.3 Global Noninvasive Vaccination Sales Volume by Type
3.3.1 Global Noninvasive Vaccination Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Noninvasive Vaccination Sales Volume, by Type (2019-2030)
3.3.3 Global Noninvasive Vaccination Sales Volume, by Type (%) (2019-2030)
3.4 Global Noninvasive Vaccination Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Public
4.1.2 Private
4.2 Global Noninvasive Vaccination Sales Value by Application
4.2.1 Global Noninvasive Vaccination Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Noninvasive Vaccination Sales Value, by Application (2019-2030)
4.2.3 Global Noninvasive Vaccination Sales Value, by Application (%) (2019-2030)
4.3 Global Noninvasive Vaccination Sales Volume by Application
4.3.1 Global Noninvasive Vaccination Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Noninvasive Vaccination Sales Volume, by Application (2019-2030)
4.3.3 Global Noninvasive Vaccination Sales Volume, by Application (%) (2019-2030)
4.4 Global Noninvasive Vaccination Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Noninvasive Vaccination Sales Value by Region
5.1.1 Global Noninvasive Vaccination Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Noninvasive Vaccination Sales Value by Region (2019-2024)
5.1.3 Global Noninvasive Vaccination Sales Value by Region (2025-2030)
5.1.4 Global Noninvasive Vaccination Sales Value by Region (%), (2019-2030)
5.2 Global Noninvasive Vaccination Sales Volume by Region
5.2.1 Global Noninvasive Vaccination Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Noninvasive Vaccination Sales Volume by Region (2019-2024)
5.2.3 Global Noninvasive Vaccination Sales Volume by Region (2025-2030)
5.2.4 Global Noninvasive Vaccination Sales Volume by Region (%), (2019-2030)
5.3 Global Noninvasive Vaccination Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Noninvasive Vaccination Sales Value, 2019-2030
5.4.2 North America Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Noninvasive Vaccination Sales Value, 2019-2030
5.5.2 Europe Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Noninvasive Vaccination Sales Value, 2019-2030
5.6.2 Asia Pacific Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Noninvasive Vaccination Sales Value, 2019-2030
5.7.2 South America Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Noninvasive Vaccination Sales Value, 2019-2030
5.8.2 Middle East & Africa Noninvasive Vaccination Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Noninvasive Vaccination Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Noninvasive Vaccination Sales Value
6.2.1 Key Countries/Regions Noninvasive Vaccination Sales Value, 2019-2030
6.2.2 Key Countries/Regions Noninvasive Vaccination Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Noninvasive Vaccination Sales Value, 2019-2030
6.3.2 United States Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Noninvasive Vaccination Sales Value, 2019-2030
6.4.2 Europe Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Noninvasive Vaccination Sales Value, 2019-2030
6.5.2 China Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.5.3 China Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Noninvasive Vaccination Sales Value, 2019-2030
6.6.2 Japan Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Noninvasive Vaccination Sales Value, 2019-2030
6.7.2 South Korea Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Noninvasive Vaccination Sales Value, 2019-2030
6.8.2 Southeast Asia Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Noninvasive Vaccination Sales Value, 2019-2030
6.9.2 India Noninvasive Vaccination Sales Value by Type (%), 2023 VS 2030
6.9.3 India Noninvasive Vaccination Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Merck
7.1.1 Merck Company Information
7.1.2 Merck Introduction and Business Overview
7.1.3 Merck Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Merck Noninvasive Vaccination Product Offerings
7.1.5 Merck Recent Development
7.2 GSK
7.2.1 GSK Company Information
7.2.2 GSK Introduction and Business Overview
7.2.3 GSK Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.2.4 GSK Noninvasive Vaccination Product Offerings
7.2.5 GSK Recent Development
7.3 Sanofi
7.3.1 Sanofi Company Information
7.3.2 Sanofi Introduction and Business Overview
7.3.3 Sanofi Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Sanofi Noninvasive Vaccination Product Offerings
7.3.5 Sanofi Recent Development
7.4 Lanzhou Institute
7.4.1 Lanzhou Institute Company Information
7.4.2 Lanzhou Institute Introduction and Business Overview
7.4.3 Lanzhou Institute Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Lanzhou Institute Noninvasive Vaccination Product Offerings
7.4.5 Lanzhou Institute Recent Development
7.5 Serum Institute
7.5.1 Serum Institute Company Information
7.5.2 Serum Institute Introduction and Business Overview
7.5.3 Serum Institute Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Serum Institute Noninvasive Vaccination Product Offerings
7.5.5 Serum Institute Recent Development
7.6 Valneva
7.6.1 Valneva Company Information
7.6.2 Valneva Introduction and Business Overview
7.6.3 Valneva Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Valneva Noninvasive Vaccination Product Offerings
7.6.5 Valneva Recent Development
7.7 Shanghai United Cell
7.7.1 Shanghai United Cell Company Information
7.7.2 Shanghai United Cell Introduction and Business Overview
7.7.3 Shanghai United Cell Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Shanghai United Cell Noninvasive Vaccination Product Offerings
7.7.5 Shanghai United Cell Recent Development
7.8 Bibcol
7.8.1 Bibcol Company Information
7.8.2 Bibcol Introduction and Business Overview
7.8.3 Bibcol Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Bibcol Noninvasive Vaccination Product Offerings
7.8.5 Bibcol Recent Development
7.9 PaxVax
7.9.1 PaxVax Company Information
7.9.2 PaxVax Introduction and Business Overview
7.9.3 PaxVax Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.9.4 PaxVax Noninvasive Vaccination Product Offerings
7.9.5 PaxVax Recent Development
7.10 Vabiotech
7.10.1 Vabiotech Company Information
7.10.2 Vabiotech Introduction and Business Overview
7.10.3 Vabiotech Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Vabiotech Noninvasive Vaccination Product Offerings
7.10.5 Vabiotech Recent Development
7.11 Tiantan Biological
7.11.1 Tiantan Biological Company Information
7.11.2 Tiantan Biological Introduction and Business Overview
7.11.3 Tiantan Biological Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Tiantan Biological Noninvasive Vaccination Product Offerings
7.11.5 Tiantan Biological Recent Development
7.12 EuBiologics
7.12.1 EuBiologics Company Information
7.12.2 EuBiologics Introduction and Business Overview
7.12.3 EuBiologics Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.12.4 EuBiologics Noninvasive Vaccination Product Offerings
7.12.5 EuBiologics Recent Development
7.13 Panacea Biotec Ltd
7.13.1 Panacea Biotec Ltd Company Information
7.13.2 Panacea Biotec Ltd Introduction and Business Overview
7.13.3 Panacea Biotec Ltd Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Panacea Biotec Ltd Noninvasive Vaccination Product Offerings
7.13.5 Panacea Biotec Ltd Recent Development
7.14 Bio-Med
7.14.1 Bio-Med Company Information
7.14.2 Bio-Med Introduction and Business Overview
7.14.3 Bio-Med Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Bio-Med Noninvasive Vaccination Product Offerings
7.14.5 Bio-Med Recent Development
7.15 Halfkin Bio-Pharmaceuticals
7.15.1 Halfkin Bio-Pharmaceuticals Company Information
7.15.2 Halfkin Bio-Pharmaceuticals Introduction and Business Overview
7.15.3 Halfkin Bio-Pharmaceuticals Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Halfkin Bio-Pharmaceuticals Noninvasive Vaccination Product Offerings
7.15.5 Halfkin Bio-Pharmaceuticals Recent Development
7.16 AstraZeneca
7.16.1 AstraZeneca Company Information
7.16.2 AstraZeneca Introduction and Business Overview
7.16.3 AstraZeneca Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.16.4 AstraZeneca Noninvasive Vaccination Product Offerings
7.16.5 AstraZeneca Recent Development
7.17 Cipla
7.17.1 Cipla Company Information
7.17.2 Cipla Introduction and Business Overview
7.17.3 Cipla Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Cipla Noninvasive Vaccination Product Offerings
7.17.5 Cipla Recent Development
7.18 BCHT
7.18.1 BCHT Company Information
7.18.2 BCHT Introduction and Business Overview
7.18.3 BCHT Noninvasive Vaccination Sales, Revenue and Gross Margin (2019-2024)
7.18.4 BCHT Noninvasive Vaccination Product Offerings
7.18.5 BCHT Recent Development
8 Industry Chain Analysis
8.1 Noninvasive Vaccination Industrial Chain
8.2 Noninvasive Vaccination Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Noninvasive Vaccination Sales Model
8.5.2 Sales Channel
8.5.3 Noninvasive Vaccination Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る